{
    "name": "megestrol",
    "comment": "Rx",
    "other_names": [
        "Megace",
        "Megace ES"
    ],
    "classes": [
        "Antineoplastics",
        "Hormones",
        "Progestins",
        "Appetite Stimulants"
    ],
    "source": "https://reference.medscape.com/drug/megace-megestrol-342783",
    "pregnancy": {
        "common": [
            "Obtain a pregnancy test in females of reproductive potential prior to initiating treatment; advise females of reproductive potential to use effective contraception while taking drug",
            "There are no available human data to assess for any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes; advise a pregnant women of potential risk to fetus",
            "Pregnancy testing is recommended prior to treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Therapy may cause fetal harm when administered during pregnancy; advise females of reproductive potential to use effective contraception during treatment"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy; there are no adequate animal developmental toxicity data at clinically relevant doses; pregnant rats treated with low doses resulted in reduction in fetal weight and number of live births, and feminization of male fetuses at doses below maximum recommended clinical dosing based on body surface area"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1; the drug is present in human milk; there are no data on effects of drug on breastfed infant or on milk production; because of potential for HIV transmission and adverse effects on a breastfed infant, instruct mothers not to breastfeed if they are receiving therapy"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known or suspected pregnancy",
                "Acute thrombophlebitis, thromboembolic disorder, breast cancer",
                "Undiagnosed abnormal genital bleeding",
                "Prophylaxis of weight loss",
                "Documented hypersensitivity",
                "May induce vaginal bleeding in women"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Diabetes mellitus",
                "History of thromboembolic disease",
                "Not to be used as prophylaxis against weight loss or as diagnostic test for pregnancy",
                "Adrenal insufficiency may occur in patients receiving or being withdrawn from long-term megestrol treatment",
                "Megestrol is a progesterone derivative which may induce vaginal bleeding in women",
                "Cushing syndrome reported with thearpy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "mavacamten",
            "description": {
                "common": "mavacamten will decrease the level or effect of megestrol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "megestrol decreases effects of insulin degludec by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "megestrol decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "megestrol decreases effects of insulin inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and megestrol both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "megestrol increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of megestrol by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "taurine",
            "description": {
                "common": "megestrol decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "mood swings",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "sweating",
            "percent": null
        },
        {
            "name": "Amenorrhea",
            "percent": null
        },
        {
            "name": "breakthrough bleeding",
            "percent": null
        },
        {
            "name": "change in menstrual flow",
            "percent": null
        },
        {
            "name": "hot sweats",
            "percent": null
        },
        {
            "name": "impotence",
            "percent": null
        },
        {
            "name": "spotting",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "flatulence",
            "percent": null
        },
        {
            "name": "indigestion",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "weight gain",
            "percent": null
        },
        {
            "name": "Deep vein thrombosis",
            "percent": null
        },
        {
            "name": "DVT",
            "percent": null
        },
        {
            "name": "Pulmonary embolism",
            "percent": null
        },
        {
            "name": "Thrombophlebitis",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Adrenal insufficiency",
            "percent": null
        }
    ]
}